RVNC250117C40000
- 0.03
- 0.000.00%
Revance Therapeutics Newsroom
Revance Therapeutics Analyst Ratings
Hold Rating Recommended Amid Competitive Bidding War for Revance Therapeutics
Crown Labs Proposed Higher Revance Bid to Save Deal
Express News | Crown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc.
Press Release: Crown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc.
Key Deals This Week: FuboTV - Disney, Constellation Energy, Eli Lilly, Phillips 66, Intercontinental Exchange and More
Mizuho Securities Maintains Revance Therapeutics(RVNC.US) With Hold Rating
Sector Update: Health Care Stocks Rise in Afternoon Trading
Sector Update: Health Care
Needham Maintains Revance Therapeutics(RVNC.US) With Hold Rating
Hold Rating Issued Amid Acquisition Uncertainty for Revance Therapeutics
Revance Therapeutics Shares Rise as Teoxane Looks to Upend Crown Deal
Teoxane: Transaction Would Be Subject to Any Applicable Regulatory Approvals
Teoxane Owns 6.2% of the Outstanding Shares of Common Stock of Revance
Express News | Teoxane: Does Not Anticipate Any Significant Regulatory Risks or Delays for Potential Revance Deal
Express News | Teoxane: Prepared to TransAct Promptly
Express News | Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in Cash
Press Release: Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in Cash
Barclays Maintains Equal-Weight on Revance Therapeutics, Lowers Price Target to $3
Analysts Offer Insights on Healthcare Companies: Revance Therapeutics (RVNC) and Neurocrine (NBIX)